Shree Ganesh Remedies Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, following a Board of Directors meeting held on January 23, 2026. The pharmaceutical company, primarily engaged in bulk drug intermediates, reported mixed performance compared to the previous year.

Standalone Financial Performance

The company's standalone results for Q3FY26 showed revenue from operations of ₹2,110.68 lakhs, representing a decline from ₹2,705.28 lakhs in Q3FY25. Net profit after tax for the quarter was ₹309.62 lakhs, down from ₹543.34 lakhs in the corresponding quarter of the previous year.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, the company reported revenue from operations of ₹7,608.96 lakhs compared to ₹8,416.46 lakhs in the previous year. Net profit after tax for the nine-month period stood at ₹1,150.11 lakhs against ₹1,650.10 lakhs in the corresponding period of the previous year.

Consolidated Results

The consolidated financial results, which include the company's wholly-owned subsidiary SGRL USA INC, showed similar trends. For Q3FY26, consolidated net profit after tax was ₹309.09 lakhs compared to ₹542.35 lakhs in Q3FY25. The nine-month consolidated net profit was ₹1,149.16 lakhs against ₹1,647.82 lakhs in the previous year.

Cost Structure and Expenses

The company's cost of materials consumed for Q3FY26 was ₹894.67 lakhs compared to ₹1,023.30 lakhs in Q3FY25. Employee benefit expenses increased to ₹286.14 lakhs from ₹266.37 lakhs. Finance costs rose significantly to ₹73.59 lakhs from ₹37.51 lakhs in the corresponding quarter of the previous year.

Corporate Information

The results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 23, 2026. The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. The company operates primarily in the business of bulk drug intermediates, which constitutes a single reportable segment.

Shree Ganesh Remedies Limited announced the re-appointment of Mr. Parth Chandulal Kothia as Whole Time Director and Chief Financial Officer for an additional five-year term. The board of directors approved this decision on January 16, 2026, based on the recommendation of the Nomination and Remuneration Committee.

Board Meeting Outcomes

The board meeting, which commenced at 4:45 PM and concluded at 6:00 PM on January 16, 2026, addressed Mr. Kothia's re-appointment as his current term expires on January 17, 2026. The re-appointment is effective from January 17, 2026, and will continue until January 16, 2031, subject to approval from the company's members.

Director Profile and Qualifications

Mr. Parth Chandulal Kothia brings significant expertise to his role as Whole Time Director and CFO. He is a graduate in Chemical Engineering and holds a Master of Science degree in Global Finance from Fordham University, USA. His professional experience spans over five years in Business Development for Pharmaceutical Intermediates and Specialty Chemicals.

Prior to joining the company, Mr. Kothia worked in the Private Equity and Venture Capital industry in the USA, gaining extensive understanding of Finance and Capital Markets. Since joining Shree Ganesh Remedies Limited in 2021, he has been instrumental in driving growth through his marketing and finance initiatives, which have had an organization-wide impact.

Shareholding and Relationships

Mr. Kothia currently holds 131,704 equity shares in the company. He is the son of Mr. Chandulal Manubhai Kothia, who serves as the Chairman and Managing Director of Shree Ganesh Remedies Limited.

Regulatory Compliance

The company confirmed that Mr. Parth Chandulal Kothia and all existing directors are not debarred from holding directorial positions by any SEBI order or other regulatory authority. This disclosure complies with stock exchange circulars dated June 20, 2018, and SEBI regulations regarding director appointments.

The re-appointment reflects the company's confidence in Mr. Kothia's leadership capabilities and his contribution to the organization's growth trajectory in the pharmaceutical sector.